$PFE Headlines Judge likely to throw the book at Martoma,

New Post Public Reply Private Reply Replies (0) Message Board

Feb 10, 2014 at 11:28 AM

$PFE Headlines

Judge likely to throw the book at Martoma, experts say 4:00 p.m. Feb. 6, 2014 - blogs.marketwatch.com
Feds, pharma rivals team up on Alzheimer's 2:32 p.m. Feb. 6, 2014 - blogs.marketwatch.com
The big Merck news centers on cancer-drug collaborations with other giants 11:02 a.m. Feb. 5, 2014 - blogs.marketwatch.com
Merck 4Q profit falls on weaker sales 8:21 a.m. Feb. 5, 2014 - MarketWatch.com
Stock market live blog: Indexes break 2-day losing streak; Kors, Yum climb 3:43 p.m. Feb. 4, 2014 - blogs.marketwatch.com
Pfizer leads Dow after an upgrade on promising cancer-drug tests 11:07 a.m. Feb. 4, 2014 - blogs.marketwatch.com
Pfizer leads Dow with 3% gain following upgrade 10:11 a.m. Feb. 4, 2014 - Russ Britt
Pfizer leads Dow with 3.3% gain following upgrade 10:03 a.m. Feb. 4, 2014 - Russ Britt
Pfizer advances 4.2% at the open, leads Dow 9:33 a.m. Feb. 4, 2014 - Victor Reklaitis
U.S. stocks see worst selloff in several months 4:41 p.m. Feb. 3, 2014 - Anora Mahmudova
Biggest drops since June for Dow industrials, S&P 500: stock market live blog recap 4:26 p.m. Feb. 3, 2014 - blogs.marketwatch.com
Pfizer, Randgold gain in slumping stock market 3:52 p.m. Feb. 3, 2014 - Saumya Vaishampayan
Pfizer shares get a boost on positive results for breast-cancer treatment 10:37 a.m. Feb. 3, 2014 - blogs.marketwatch.com
Pfizer breast-cancer study meets endpoint 8:37 a.m. Feb. 3, 2014 - MarketWatch.com
The inscrutable gold timers 10:26 a.m. Jan. 30, 2014 - Mark Hulbert
Updates, advisories and surprises 5:31 p.m. Jan. 28, 2014 - MarketWatch
U.S. stocks rise; Dow breaks 5-day skid 5:02 p.m. Jan. 28, 2014 - Anora Mahmudova
Stocks rebound, helping Dow quit loss streak; Yahoo drops after hours (Stock market live blog recap) 4:31 p.m. Jan. 28, 2014 - blogs.marketwatch.com
Newscast: Stocks back in the win column 4:27 p.m. Jan. 28, 2014 - MarketWatch
Apple sees worst day in a year; Casablanca lifts Cliffs 3:10 p.m. Jan. 28, 2014 - Ben Eisen

Dividend Stocks: Safety or Sabotage? 33 min ago - TheStreet.com
PBYI: Why Puma Biotechnology Shares Are Soaring 4:09 a.m. Today - InvestorPlace.com
FDA Panel to Weigh Painkillers' Cardiac Risk 4:32 p.m. Feb. 9, 2014 - WSJ.com
Now Everything Is Crystal Clear 2:46 a.m. Feb. 9, 2014 - Seeking Alpha
Pfizer Inc (PFE): Today's Featured Drugs Winner 5:00 p.m. Feb. 7, 2014 - TheStreet.com
Dow 30 Stock Roundup: Disney Stars, Chevron Tanks - Analyst Blog 11:12 a.m. Feb. 7, 2014 - Zacks.com
The Best of Blackrock Funds: 4 Top Funds 8:26 a.m. Feb. 7, 2014 - InvestorPlace.com
Martoma Convicted in Historic Insider-Trading Case 2:21 p.m. Feb. 6, 2014 - FOXBusiness
Emerging Market Misery And U.S. Large-Cap Euphoria 12:23 p.m. Feb. 6, 2014 - Seeking Alpha
March 14th Options Now Available For Pfizer (PFE) 10:53 a.m. Feb. 6, 2014 - TheStreet.com
Irving Kahn's Kahn Brothers' Top Five Stocks at Year-End 9:34 a.m. Feb. 6, 2014 - GuruFocus.com
The 4 Stocks That Dominated the Market on Wednesday 3:43 p.m. Feb. 5, 2014 - 247WallSt.com
Merck in Pacts to Study Cancer Treatment 2:48 p.m. Feb. 5, 2014 - WSJ.com
Merck Misses on Earnings by a Penny - Analyst Blog 12:12 p.m. Feb. 5, 2014 - Zacks.com
5 Stocks Pushing The Drugs Industry Downward 12:03 p.m. Feb. 5, 2014 - TheStreet.com
Merck Q4 Misses, But Cancer Deals Ignite Stock 10:48 a.m. Feb. 5, 2014 - Investors Business Daily
Stock Market News for February 05, 2014 - Market News 10:06 a.m. Feb. 5, 2014 - Zacks.com
Merck Misses Estimates in 4Q; Plans Increased Focus on Cancer 10:05 a.m. Feb. 5, 2014 - FOXBusiness
Dow Today: Merck (MRK) Leads The Day Higher, Pfizer (PFE) Lags 10:00 a.m. Feb. 5, 2014 - TheStreet.com
Healthcare Stocks: No Longer a Sure Thing 7:50 a.m. Feb. 5, 2014 - InvestorPlace.com

Pfizer And Merck To Collaborate On Innovative Anti-Cancer Combination Studies 6:45 a.m. Feb. 5, 2014 - BusinessWire - BZX
Pain Therapeutics Reports 2013 Financial Results and Provides Guidance for 2014 10:48 p.m. Feb. 4, 2014 - GlobeNewswire
LiveWorld and Pfizer to Present a Series of Panels on Social Media Within Regulated Industries at Social Media Week 10:00 a.m. Feb. 4, 2014 - BusinessWire - BZX
Biotech News for Advancing Pharma Stocks: Company's Test Results Surpass Expectations For $3.5 Billion ADHD Market 9:05 a.m. Feb. 4, 2014 - PR Newswire - PRF
TrendingWallStreet.com Initiates Trend Analysis on GFOX, CMCSA, SKTO, and PFE 12:22 a.m. Feb. 4, 2014 - ACCESSWIRE
Pfizer Announces Positive Top-Line Results From PALOMA-1 Evaluating Palbociclib Plus Letrozole in Women with Advanced Breast Cancer 7:00 a.m. Feb. 3, 2014 - BusinessWire - BZX
Critical Alerts For Twitter, Alexion Pharmaceuticals, Pfizer, Ctrip, and AngloGold Ashanti Released By InvestorsObserver 9:31 a.m. Jan. 31, 2014 - PR Newswire - PRF
Pfizer Reports Fourth-Quarter and Full-Year 2013 Results;Provides 2014 Financial Guidance 7:01 a.m. Jan. 28, 2014 - BusinessWire - BZX
Pfizer Announces Top-Line Results From Two Phase 3 Trials Of Dacomitinib In Patients With Refractory Advanced Non-Small Cell Lung Cancer 7:00 a.m. Jan. 27, 2014 - BusinessWire - BZX
Pfizer Reports Top-Line Results From ALO-02 Phase 3 Study 8:00 a.m. Jan. 23, 2014 - BusinessWire - BZX
Pharmerging Markets 2012-2016 11:12 a.m. Jan. 22, 2014 - PR Newswire - PRF
New Survey Reveals What Match.Com Members Think About Smoking Cigarettes And Dating 10:00 a.m. Jan. 22, 2014 - BusinessWire - BZX
Lpath Granted Key U.S. Patent Related to Ocular Drug Program, iSONEP 7:30 a.m. Jan. 22, 2014 - PR Newswire - PRF
CHANTIX®/CHAMPIX® (varenicline) Demonstrates Smoking-Cessation Efficacy In Smokers Unwilling or Unable To Quit Abruptly 8:00 a.m. Jan. 21, 2014 - BusinessWire - BZX
ViiV Healthcare's new HIV medicine Tivicay™ (dolutegravir) is approved in Europe 6:52 a.m. Jan. 21, 2014 - PR Newswire - PRF
Statement from Pfizer Chief Medical Officer on the 50th Anniversary of the First Surgeon General's Report on Smoking and Health 10:15 a.m. Jan. 17, 2014 - BusinessWire - BZX
Collaborations, Conference Participation Schedules, and Upcoming Earnings Release - Research Report on Pfizer, Humana, WellPoint, Stryker, and Centene 8:00 a.m. Jan. 14, 2014 - PR Newswire - PRF
Companies Aligned to Capitalize on New Japanese Regenerative Medicine Initiatives 10:09 a.m. Jan. 13, 2014 - ACCESSWIRE
Portola Pharmaceuticals Enters Second Clinical Collaboration Agreement With Bristol-Myers Squibb and Pfizer to Study Andexanet Alfa* (PRT4445), Investigational Factor Xa Inhibitor Reversal Agent, With Eliquis 8:00 a.m. Jan. 13, 2014 - GlobeNewswire
Avillion Group Partners with Pfizer to Co-develop BOSULIF® (bosutinib) as First-Line Treatment for Patients with Chronic Myelogenous Leukemia 8:47 a.m. Jan. 9, 2014 - PR Newswire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

IASLC Boosts Global Thoracic Cancer Collaboration

Breaking Down Barriers in Thoracic Oncology Picture a world where financial walls don't block innovation and knowledge sharing in cancer treatment. The International Association for the Study of Lung Cancer (IASLC) is leading the charge here. They've just launched a new initiative offering complimentary full membership to qualified healthcare professionals in low- and...

Nocpix Unveils ACE 2 Thermal Riflescope Lineup

ACE 2: A Thermal Riflescope That Promises More Let’s dive right into the nitty-gritty of Nocpix’s latest move. On September 12, they launched the ACE 2 Series—the next-gen beast of their flagship thermal riflescope lineup. A step up from the original ACE, this series aims to redefine what hunters can expect from a riflescope, introducing three models: ACE 2 S60R,...

ARTiSTORY's Strategic Advance in Cultural IP Licensing

Call it a seismic shift or call it common sense, but ARTiSTORY's recent haul of accolades makes it clear: they're onto something big in the cultural IP game. Receiving four honors at the 26th International Advertising Institute Awards (IAI Awards), including a Gold for their British Library × CHAGEE collaboration, and jumping into License Global's Top 60, they're staking...

PathoSearch: A New Era in Pathology With Visual Search

Revolutionizing Pathology with a Visual Search Engine In an era where time is money and precision is paramount, Aignostics is betting big on transforming the pathology landscape. Today, their announcement of PathoSearch, a visual search engine designed for retrieving comparable diagnosed pathology cases, marks a massive leap towards streamlining the diagnostic process....

Delhi Pushes Innovation Against Dryland Challenges

Evolution of South-South Agricultural Cooperation Let's just say if there's a time to shine a spotlight on the arid lands of our world, it's now. The Global Drylands Congress 2026 in New Delhi put a sharp focus on scaling agricultural innovation across these thirsty regions. With climate change breathing down our necks, talking shop about food security isn't just for show...

SystImmune's Data on Iza-bren Show Promise for Lung Cancer

Stepping into New Territory with SystImmune Amid the cacophony of biotech whispers and the marketplace hum, SystImmune is trotting out something that might just make the folks in lab coats raise an eyebrow. They’ve got new data for Iza-bren—none of that flashy PR chatter—but it's damn promising if you ask me. At the World Conference on Lung Cancer in Seoul,...

Countries Eye New Investment Paths at CIFIT 2026

Global Investment Winds Shift at CIFIT In the thick of a world that's being turned on its head, you've got big shots from 129 countries and 30 international organizations talking shop at the 26th China International Fair for Investment and Trade (CIFIT) in Xiamen. Take your pick from the 48 of the world's top 50 GDP powerhouses rubbing shoulders there—this ain't your...

Silk Road Maritime Extends Its Global Reach in 2026

China-Europe Trade Ties Continue to Tighten You ever watch a cargo ship glide into port and think, "There's a piece of the future right there”? Well, that's the scene at Poland’s Gdansk Port, now officially etched into the Silk Road Maritime route. This ain't just a couple of extra boats cutting through choppy waters—it's a great leap forward for a strained global...